RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-04-30
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $557000.00 | $717000.00 | $617000.00 | $383000.00 | $300000.00 | $300000.00 | $262000.00 | $3.73M | $413000.00 | $15.32M | $77.80M | $132.56M | $234.04M |
| Revenue growth (YoY) | — | +28.7% | -13.9% | -37.9% | -21.7% | +0.0% | -12.7% | +1323.3% | -88.9% | +3610.7% | +407.7% | +70.4% | +76.5% |
| Cost of revenue | $5000.00 | $36.73M | $36.96M | $50.38M | $2.00M | $76.01M | $116.29M | $92.50M | $102.86M | $4.77M | $23.41M | $51.67M | $152.16M |
| Gross profit | $552000.00 | $717000.00 | $617000.00 | $383000.00 | $-1.70M | $300000.00 | $262000.00 | $-88.77M | $-102.45M | $10.56M | $54.39M | $80.90M | $81.88M |
| Gross margin | 99.1% | 100.0% | 100.0% | 100.0% | -565.0% | 100.0% | 100.0% | -2380.6% | -24805.8% | 68.9% | 69.9% | 61.0% | 35.0% |
| R&D | $22.73M | $32.71M | $27.83M | $33.39M | $47.53M | $50.38M | $80.36M | $92.50M | $102.86M | $125.80M | $116.25M | $101.29M | $79.41M |
| SG&A | — | — | $11.01M | $19.04M | $25.09M | $29.07M | $37.40M | $53.86M | $62.01M | $149.74M | $28.31M | $4.24M | $38.81M |
| Operating income | $-27.74M | $-43.19M | $-38.23M | $-52.05M | $-72.32M | $-88.22M | $-120.42M | $-142.63M | $-164.46M | $-273.16M | $-274.68M | $-272.17M | $-316.78M |
| Operating margin | -4979.9% | -6023.2% | -6195.3% | -13590.1% | -24105.7% | -29405.0% | -45963.4% | -3825.0% | -39820.6% | -1782.5% | -353.1% | -205.3% | -135.4% |
| EBITDA | $-25.57M | $-41.51M | $-38.63M | $-52.24M | $-72.41M | $-78.52M | $-116.61M | $-139.38M | $-159.23M | $-259.31M | $-255.18M | $-305.52M | $-290.64M |
| EBITDA margin | -4590.7% | -5789.1% | -6260.5% | -13639.7% | -24137.7% | -26173.7% | -44508.4% | -3737.8% | -38554.5% | -1692.1% | -328.0% | -230.5% | -124.2% |
| EBIT | $-27.55M | $-43.28M | $-40.51M | $-54.29M | $-74.41M | $-79.97M | $-118.08M | $-141.11M | $-162.14M | $-269.56M | $-275.04M | $-339.25M | $-304.33M |
| Interest expense | $17.79M | $28.96M | $15.16M | $10.67M | $1.19M | $1.08M | $457000.00 | $44000.00 | $2.15M | $15.15M | $6.27M | $16.47M | $19.36M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-44.86M | $-58.26M | $-52.45M | $-62.92M | $-73.48M | $-89.27M | $-120.59M | $-142.57M | $-156.22M | $-282.09M | $-286.82M | $-356.42M | $-323.99M |
| Net income growth (YoY) | — | -29.9% | +10.0% | -20.0% | -16.8% | -21.5% | -35.1% | -18.2% | -9.6% | -80.6% | -1.7% | -24.3% | +9.1% |
| Profit margin | -8054.4% | -8125.4% | -8500.5% | -16427.4% | -24492.0% | -29756.7% | -46025.6% | -3823.2% | -37824.9% | -1840.7% | -368.7% | -268.9% | -138.4% |